1. N-terminal pro-B-type natriuretic peptide levels pre-transcatheter aortic valve implantation and relationship with long-term outcomes
- Author
-
Louise Marqvard Sørensen, Jeppe Kofoed Petersen, Jarl Emanuel Strange, Lauge Østergaard, Jacob Eifer Møller, Morten Schou, Lars Køber, Ole de Backer, and Emil Fosbøl
- Subjects
N-Terminal Pro-B-Type Natriuretic Peptide ,NT-proBNP ,Transcatheter Aortic Valve ,Implantation ,TAVI ,Aortic Valve Replacement ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Blood levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been suggested as a future guidance tool for the selection of patients for aortic valve replacement. This study aimed to examine how levels of NT-proBNP pre-transcatheter aortic valve implantation (TAVI) is associated with one-year rates of heart failure (HF) admission and mortality following TAVI. Methods: With Danish nationwide registries, we identified all patients undergoing TAVI from 2014 to 2021 who had at least one recorded NT-pro-BNP measurement within one year before TAVI. Patients were compared by quartiles of pre-TAVI NT-proBNP: quartile 4 (high NT-proBNP group) vs quartile 1–3 (low NT-proBNP group). Comparisons of all-cause mortality and HF-admissions were conducted using Kaplan-Meier analysis, cumulative incidence, and Cox analysis, as appropriate. Results: We identified 1,140 patients undergoing first-time TAVI with a recorded NT-pro-BNP; 846 (74.2 %) with a low NT-proBNP (
- Published
- 2024
- Full Text
- View/download PDF